Sponsor Deadline:
Letter of Intent Deadline:
Sponsor:
UI Contact:
Updated Date:
The Tau Pipeline Enabling Program (T-PEP) seeks to accelerate the discovery of potential new therapies for tauopathies.
The intent of this program is to enrich the pipeline for therapy development by facilitating the translation of academia-derived ideas into practical application. In short, it bridges the gap between innovative but resource-constrained researchers and the larger pharmaceutical companies that are looking for drug candidates to be taken into human trials.
Proposals responding to this program may focus on the toxicity of tau directly and/or they may target their studies on potential neurobiological mechanisms that promote or synergize tau formation or toxicity, e.g., calcium dyshomeostatis, mitochondrial dysfunction, neuroinflammation, microtubule stability (or instability) and function, axon transport, synapse dysfunction/loss, and other tau-related mechanisms. Applications addressing related mechanisms must include the clear rationale that it will prevent, reduce, remove, or otherwise mitigate the toxic effects of tau build-up. Funds awarded under this program must be used for lead optimization or IND-enabling studies, including cGMP scale-up/manufacture and animal efficacy studies.
